ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Dan Su
Matched on OpenAlex author ID A5140175460. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2022: 1 paper · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 7
- circFOXP1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Regulating EREG/MAPK/ERK Axis. First author DOI 10.1111/jcmm.71230↗
- E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Co-author DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
- Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Co-author DOI 10.1016/j.canlet.2023.216423↗
- PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
- Epidemiology of pancreatic cancer: New version, new vision. Co-author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
- HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jinxin Tao · 6 shared papers, 2022–2024 · strength 1.03
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Yueze Liu · 6 shared papers, 2022–2024 · strength 1.03
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Taiping Zhang · 6 shared papers, 2022–2024 · strength 1.03
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Jiangdong Qiu · 5 shared papers, 2023–2024 · strength 0.89
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Wenhao Luo · 3 shared papers, 2023–2024 · strength 0.56
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Ruobing Wang · 3 shared papers, 2023–2024 · strength 0.54
- Paper E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. DOI 10.1016/j.freeradbiomed.2024.05.031↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03↗
- Gang Yang · 3 shared papers, 2022–2023 · strength 0.50
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic can… DOI 10.1007/s13402-023-00836-3↗
- Paper HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signa… DOI 10.1002/mc.23420↗
- Fangyu Zhao · 3 shared papers, 2022–2023 · strength 0.50
- Paper PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. DOI 10.1016/j.heliyon.2023.e17194↗
- Paper Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic can… DOI 10.1007/s13402-023-00836-3↗
- Paper HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signa… DOI 10.1002/mc.23420↗
- Jun Wang · 2 shared papers, 2023 · strength 0.33
- Guangyu Chen · 2 shared papers, 2022–2023 · strength 0.31
- Paper Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic can… DOI 10.1007/s13402-023-00836-3↗
- Paper HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signa… DOI 10.1002/mc.23420↗
- Yupei Zhao · 2 shared papers, 2022–2023 · strength 0.31
- Paper Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic can… DOI 10.1007/s13402-023-00836-3↗
- Paper HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signa… DOI 10.1002/mc.23420↗
- Lei You · 2 shared papers, 2022–2023 · strength 0.30
- Leyi Huang · 1 shared paper, 2026 · strength 0.29
- Quanbo Zhou · 1 shared paper, 2026 · strength 0.29
- Xiaofeng Guo · 1 shared paper, 2026 · strength 0.29
- Rihua He · 1 shared paper, 2026 · strength 0.29
- Mengyu Feng · 1 shared paper, 2023 · strength 0.18
- Haowei Ma · 1 shared paper, 2023 · strength 0.17
- Jianchun Xiao · 1 shared paper, 2023 · strength 0.17
- Hua Huang · 1 shared paper, 2023 · strength 0.17
- Wenhao Luo · 1 shared paper, 2023 · strength 0.16
- Jiangdong Qiu · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.